Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.
Moderna (NASDAQ: MRNA) waited a long time to reach this important moment: the authorization of its vaccine in infants and children. This month, the FDA authorized the vaccine for both teens and children ages six months and older, and vaccine rollout has begun for the youngest group. Could this new authorization be Moderna's ticket to long-term success?
The biotech industry hasn't performed well this year, even by the standards of the struggling stock market. The SPDR S&P Biotech ETF -- an industry benchmark -- is down by 36% year to date. The good news is that there are still plenty of great biotech stocks that could be solid long-term picks.